Established in 2015, 2eyesVision has developed the SimVis, an innovative medical device that allows the simulation of intraocular or contact lenses for patients affected by presbyopia or cataracts.
Founded in Madrid, the company is a spin-off of the Visual Optics and Biophotonics Lab at Spanish Research Institute CSIC.
The team at 2eyesVision has developed the SimVis, a medical device that allows the simulation of different kinds of intraocular or contact lenses for the visual corrections of patients affected by presbyopia or cataracts.
The SimVis is a see-through device that simulates how a patient will see before surgery. This is of great help both for the clinician, that has to recommend a specific lens, and for the patient, who reduces uncertainty and potential post-surgery rejections.
For those patients to be treated with contact lenses, the device reduces the trial and error phase until the patient moves ahead with a specific lens.
Bullnet Capital invested in 2eyesVision in June of 2017 and has continued supporting the project ever since.